The executive meeting of the State Council held on January 10 pointed out that in recent years, the reform of centralized procurement of drugs and high-value medical consumables has been continuously promoted, and the market-oriented mechanism has effectively squeezed the falsely high medical prices. By the end of last year, a total of 260 billion yuan of medical insurance and patient expenditure had been saved. At the same time, it has also promoted pharmaceutical enterprises to devote more energy to product research and development and improve quality. Next, we should promote the normalization and institutionalization of centralized volume procurement, speed up the expansion, and continue to reduce pharmaceutical prices to benefit patients. Since its launch in 2018, the state has organized six rounds of seven rounds of centralized drug procurement. The contents of the purchase are expanded from chemical drugs to biological drugs and high value medical consumables, covering drugs and consumables in areas such as hypertension, diabetes, coronary heart disease, gastrointestinal diseases, malignant tumors, Department of orthopedics trauma, and so on. In 2021, the procurement of implantable consumables such as cardiac stents and joints was implemented one after another, and the first biological drug insulin, "local alliance version" Chinese patent medicine, "eight provinces and two districts" centralized procurement of implant teeth was officially carried out. Following the pace of 2021, the centralized volume procurement will fully advance to the deep water area in 2022, and the objects of volume procurement will no longer have restricted areas. "The national organization of volume procurement not only reduces the medical insurance fund expenditure and patient burden, improves the quality of patient medication, but also improves the hospital income and expenditure structure, gives the hospital room for reform, more time and motivation to improve the service quality, and significantly improves the patient satisfaction." Cai Daozhang, President of the Third Affiliated Hospital of Southern Medical University, said in an interview with the economic information daily that in the past, a lot of time was spent communicating with patients about the use of consumables before surgery. Now communication in this regard has been significantly reduced, patients' acceptance of expenditure has increased significantly, and most purchased varieties can meet clinical needs. Taking the Third Affiliated Hospital of Southern Medical University as an example, the number of operations has increased significantly due to the decline in the prices of related drugs and consumables. The national Standing Committee has defined the work priorities for centralized volume procurement in 2022. The meeting pointed out that first, focusing on chronic diseases and common diseases, we will continue to promote the centralized purchase of drugs at the national level, and all localities will carry out provincial or inter provincial alliance procurement of drugs purchased outside the national centralized purchase. By the end of this year, the national and provincial centralized procurement of drugs will reach more than 350 in each province. Second, gradually expand the coverage of centralized collection of high-value medical consumables, and carry out centralized collection of orthopaedic consumables, drug balloons and dental implants concerned by the masses at the national and provincial levels respectively. Third, ensure the long-term stable supply of selected drugs and consumables, strengthen supervision, and ensure that the prices of selected products do not degrade. Medical institutions should give reasonable priority to the use of the selected products. Fourth, implement the policy of retaining the balance of centralized medical insurance funds, promote the reform of the salary system, reasonably increase the income of medical personnel and better mobilize their enthusiasm. For the meeting's proposal of "centralized collection of orthopaedic consumables, drug balloons and dental implants concerned by the masses at the national and provincial levels", there have been actions before. Recently, the state organized the joint procurement platform of medical consumables to release the notice on carrying out the centralized maintenance of orthopaedic external fixation medical consumables information and the notice on carrying out the selected catalogue of orthopaedic trauma medical consumables associated with the orthopaedic trauma medical consumables alliance in 12 provinces. In addition, enterprises related to spinal medical consumables will receive digital certificates before January 14. In 2021, there was a precedent for intensive collection of dental implants. In August 2021, Ningbo Medical Insurance Bureau launched the "first shot" of intensive dental implant purchase, interviewed five imported dental implant suppliers, and said that they wanted to return the dental implant to a reasonable price range. In November of the same year, Sichuan Province issued the "eight provinces and two districts" notice on carrying out information collection of some oral high-value medical consumables products, and the declared product scope involves some medical consumables constituting the oral implant system. Various signs show that the centralized mining in the field eagerly expected by the people will accelerate in 2022. Jin Weijia, party secretary and director of Anhui Medical Security Bureau, said that there is no unified industry standard and product code for medical consumables, so it is difficult to compare quality and price between products and form in-depth competition in the industry. Relevant enterprises maintain their own sales channels, and the virtual high price of high-value consumables is like a "solid ice" that is difficult to break. However, generally speaking, there is no restricted area for adhering to the people-centered and reform. In the future, "no restricted area" centralized mining is expected to further reduce the burden of medical treatment. But at the same time, we also need to recognize that the fundamental goal of medical reform is to squeeze the water of drug consumables, promote the adjustment of income structure of medical institutions, straighten out the price system of medical services, reform the salary system of medical personnel, and realize the linkage of three doctors and multiple benefits. Wu Ming, assistant director of the medical department of Peking University, said that in the past, medical institutions did not establish a cost control and profit-making mechanism, resulting in rebate competition and pricing failure due to loopholes in the pharmaceutical market. However, with the in-depth promotion of centralized volume procurement, this problem has been obviously corrected. While implementing the retention of medical insurance funds and promoting the efficient use of funds, we should realize the "cage for bird" and promote medical institutions to actively establish a cost control and profit-making mechanism. "Centralized procurement with quantity is not the only way to win the bid at a low price. Enterprises are not encouraged to compete maliciously and compete excessively regardless of cost." Wu Ming said that the national centralized procurement policy will continue to be improved. In recent years, the state has achieved remarkable results in centralized procurement, and is constantly revising procurement rules to reduce prices without degrading quality. For example, from the purchase of insulin and bone and joint belt, it is obvious that the purchase rules not only consider the quality and supply, but also increase the proportion of clinical demand. It is a general trend to collect and respect clinical practice. For the next step to improve the centralized purchase rules, Cai Daozhang suggested that on the basis of considering the supply varieties and supply guarantee of enterprises, various indicators such as the original curative effect, real curative effect and service life of products can be added to make the price competition more reasonable and let people really use drugs and consumables with better quality and price. Some insiders also said that in the future, under the background of the normalization of centralized and volume procurement, we can further refine the detailed rules for the evaluation of centralized procurement, study the micro innovation procurement policy, encourage relevant enterprises to strengthen quality control, strengthen product innovation, and promote the healthy and orderly development of the industry. (outlook new era)